At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 365 enrolled
Drug / intervention
REGN910-3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating REGN910-3 and Intravitreal Aflibercept Injection (IAI) for Neovascular Age-Related Macular Degeneration. Completed, enrolled 365 participants across 87 sites.
Detailed Summary
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMar 2016
Primary CompletionOct 2017
TodayJul 2026
First PostedMar 18, 2016
Enrollment StartMar 31, 2016
Primary CompletionOct 3, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.3 years ago
Interventions
REGN910-3drug
Intravitreal Aflibercept Injection (IAI)drug